AU2008284271B2 - Matriptase protein and uses thereof - Google Patents

Matriptase protein and uses thereof Download PDF

Info

Publication number
AU2008284271B2
AU2008284271B2 AU2008284271A AU2008284271A AU2008284271B2 AU 2008284271 B2 AU2008284271 B2 AU 2008284271B2 AU 2008284271 A AU2008284271 A AU 2008284271A AU 2008284271 A AU2008284271 A AU 2008284271A AU 2008284271 B2 AU2008284271 B2 AU 2008284271B2
Authority
AU
Australia
Prior art keywords
cancer
matriptase
matriptase stem
stem
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008284271A
Other languages
English (en)
Other versions
AU2008284271A1 (en
Inventor
Christian Rohlff
Jonathan Alexander Terrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biotherapeutics Ltd
ER Squibb and Sons LLC
Original Assignee
Oxford Biotherapeutics Ltd
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biotherapeutics Ltd, ER Squibb and Sons LLC filed Critical Oxford Biotherapeutics Ltd
Publication of AU2008284271A1 publication Critical patent/AU2008284271A1/en
Assigned to MEDAREX, L.L.C., OXFORD GENOME SCIENCES (UK) LTD. reassignment MEDAREX, L.L.C. Amend patent request/document other than specification (104) Assignors: MEDAREX, INC., OXFORD GENOME SCIENCES (UK) LTD.
Assigned to MEDAREX, L.L.C., OXFORD BIO THERAPEUTICS LTD reassignment MEDAREX, L.L.C. Alteration of Name(s) of Applicant(s) under S113 Assignors: MEDAREX, L.L.C., OXFORD GENOME SCIENCES (UK) LTD.
Assigned to OXFORD BIOTHERAPEUTICS LTD, MEDAREX, L.L.C. reassignment OXFORD BIOTHERAPEUTICS LTD Alteration of Name(s) of Applicant(s) under S113 Assignors: MEDAREX, L.L.C., OXFORD BIO THERAPEUTICS LTD
Application granted granted Critical
Publication of AU2008284271B2 publication Critical patent/AU2008284271B2/en
Assigned to OXFORD BIOTHERAPEUTICS LTD, E. R. SQUIBB & SONS, L.L.C. reassignment OXFORD BIOTHERAPEUTICS LTD Request to Amend Deed and Register Assignors: MEDAREX, L.L.C., OXFORD BIOTHERAPEUTICS LTD
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2008284271A 2007-08-07 2008-08-07 Matriptase protein and uses thereof Ceased AU2008284271B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96383707P 2007-08-07 2007-08-07
US60/963,837 2007-08-07
PCT/US2008/009512 WO2009020645A2 (en) 2007-08-07 2008-08-07 Matriptase protein and uses thereof

Publications (2)

Publication Number Publication Date
AU2008284271A1 AU2008284271A1 (en) 2009-02-12
AU2008284271B2 true AU2008284271B2 (en) 2014-03-13

Family

ID=40239716

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008284271A Ceased AU2008284271B2 (en) 2007-08-07 2008-08-07 Matriptase protein and uses thereof

Country Status (7)

Country Link
US (1) US8420091B2 (OSRAM)
EP (1) EP2185933B1 (OSRAM)
JP (2) JP5864856B2 (OSRAM)
AU (1) AU2008284271B2 (OSRAM)
DK (1) DK2185933T3 (OSRAM)
ES (1) ES2550754T3 (OSRAM)
WO (1) WO2009020645A2 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120294800A1 (en) * 2009-01-07 2012-11-22 University Of Medicine And Dentistry Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
LT2403878T (lt) * 2009-03-05 2017-10-10 E. R. Squibb & Sons, L.L.C. Pilnai žmogaus specifiniai antikūnai, skirti cadm1
CA2818237C (en) 2009-11-18 2021-05-18 University Of Medicine And Dentistry Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
US9849192B2 (en) 2009-11-18 2017-12-26 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
EP2904015A4 (en) 2012-10-02 2016-10-05 Univ Rutgers TARGETED RELEASE OF ANTIBODIES TO ACTIVATED MATRIPTASE-CONJUGATED TOXINS
AR098523A1 (es) * 2013-11-25 2016-06-01 Oxford Biotherapeutics Ltd Anticuerpos dirigidos contra matriptasa y composiciones relacionadas
EP3217175B1 (en) * 2014-11-07 2020-12-23 Fujikura Kasei Co., Ltd. Arteriosclerosis detection method using deoxyhypusine synthase gene as indicator
JP7145374B2 (ja) 2016-03-18 2022-10-03 ラトガース ザ ステイト ユニバーシティー オブ ニュージャージー インビボでの切断可能連結部分によって抗マトリプターゼ抗体にコンジュゲートされた化学療法剤を用いる腫瘍細胞の標的化

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047796A2 (en) * 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972616A (en) 1998-02-20 1999-10-26 The Board Of Trustees Of The University Of Arkansas TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas
US7022821B1 (en) * 1998-02-20 2006-04-04 O'brien Timothy J Antibody kit for the detection of TADG-15 protein
JP4778617B2 (ja) 1999-03-12 2011-09-21 ジョージタウン ユニバーシティ マトリプターゼ、セリンプロテアーゼおよびその応用
US7030231B1 (en) * 1999-09-30 2006-04-18 Catalyst Biosciences, Inc. Membrane type serine protease 1 (MT-SP1) and uses thereof
EP1226150A4 (en) * 1999-10-20 2005-05-25 Univ Arkansas TADG-15: EXTRACELLULAR SERINE PROTEASE EXPRESSED IN CARCINOMA
US6447978B1 (en) 1999-12-03 2002-09-10 Kodak Polychrome Graphics Llc Imaging member containing heat switchable polymer and method of use
CA2396774A1 (en) 2000-02-03 2001-08-09 Corvas International, Inc. Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US6903201B2 (en) 2001-01-05 2005-06-07 Curagen Corporation Proteins and nucleic acids encoding same
WO2002072786A2 (en) 2001-03-13 2002-09-19 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
WO2002077263A2 (en) 2001-03-22 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
KR20030096292A (ko) 2001-03-27 2003-12-24 덴드레온 샌 디에고 엘엘씨 트랜스막 세린 프로테아제 9를 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
KR20040080940A (ko) 2001-05-14 2004-09-20 덴드레온 코포레이션 트랜스막 세린 프로테아제 10을 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
US7019019B2 (en) 2002-12-23 2006-03-28 Dendreon Corporation Matriptase inhibitors and methods of use
BRPI0418942B1 (pt) 2004-07-09 2018-05-29 Telefonaktiebolaget Lm Ericsson Método para prover serviços diferentes em um sistema de comunicação de multimídia, e, servidor de aplicativo em um sistema de comunicação de multimídia
WO2006068975A2 (en) 2004-12-20 2006-06-29 Abgenix, Inc. Binding proteins specific for human matriptase
EP1851543A2 (en) 2005-02-24 2007-11-07 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007047796A2 (en) * 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
abcam® 'Anti-ST14 antibody (ab28267)' [retrieved on 7 February 2013]. Retrieved from the Internet <URL: http://www.abcam.com/ST14-antibody-ab28267.html?refer404=catalogue%2028267 *
abcam® Scientific Support and Customer Services response to an inquiry, 'Anti-ST14 antibody (ab28267)' [retrieved on 7 February 2013]. Retrieved from the Internet <URL: http://www.abcam.com/ST14-antibody-ab28267-support.html *
abcam® 'ST14 peptide (Stem region) (ab41263)' [retrieved on 7 February 2013]. Retrieved from the Internet <URL: http://www.abcam.com/ab41263.html *
CHO, E. G., et al., The Journal of Biological Chemistry, 2001, vol. 276, pages 44581-44589 *
TSUZUKI, S., et al., Biochemical Journal, 2005, vol. 388, pages 679-687 *

Also Published As

Publication number Publication date
ES2550754T3 (es) 2015-11-12
WO2009020645A3 (en) 2009-05-07
US20100285017A1 (en) 2010-11-11
JP5864856B2 (ja) 2016-02-17
JP2014223083A (ja) 2014-12-04
JP2010535506A (ja) 2010-11-25
US8420091B2 (en) 2013-04-16
EP2185933B1 (en) 2015-10-07
AU2008284271A1 (en) 2009-02-12
DK2185933T3 (en) 2015-10-26
EP2185933A2 (en) 2010-05-19
WO2009020645A2 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
JP5945381B2 (ja) タンパク質
US8540998B2 (en) Methods for treating cancer using ephrin type-A receptor 10 antibodies conjugated to cytotoxic agents
US8420091B2 (en) Matriptase protein and uses thereof
US20190310255A1 (en) Proteins
US8084034B2 (en) Proteins
EP2200636A1 (en) Protein
US20110229480A1 (en) Pta072 protein
EP2447719A1 (en) Proteins
US8652478B2 (en) Method for treating cancer by administering antibody to ephrin type-A receptor 7
US20120058131A1 (en) Pta089 protein

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired